• Joanna Zdziarska, Magdalena Górska-Kosicka, Michał Jamrozik, Justyna Kozińska, Maria Podolak-Dawidziak, Ewa Stefańska-Windyga, Krystyna Zawilska, and Krzysztof Chojnowski.
• Department of Hematology, University Hospital in Krakow, Kraków, Poland. jzdziarska@su.krakow.pl
• Pol. Arch. Med. Wewn. 2022 Aug 22; 132 (7-8).

IntroductionPatient adherence to a prophylactic regimen is important for optimal benefit of hemophilia treatment. Despite a growing number of adults with hemophilia in Poland receiving secondary prophylaxis, data on adherence to the regimen are limited.ObjectivesThe aim of the study was to assess adherence to secondary prophylaxis in Polish adults with severe hemophilia.Patients And MethodsPatients were recruited in 18 hemophilia treatment centers in Poland. Adherence to prophylaxis was assessed with the Validated Hemophilia Regimen Treatment Adherence Scale Prophylaxis (VERITAS‑Pro) questionnaire.ResultsData on 270 men on the prophylactic regimen (median [interquartile range, IQR] age, 37 [18-75] years; mean [SD], 38.2 [13.3] years) were analyzed. Median (IQR) VERITAS‑Pro score for the study population was 36 (24-76) years; mean (SD), 37.7 (9.9) years, indicating general adherence to the prophylactic regimen. The median subscale scores ranged from 4 for Dosing to 8 for Planning (means, 5.6 and 7.7, respectively). The most pronounced difference in the subscale scores between adherent and nonadherent patients was recorded for Dosing (median, 4 vs 10; mean, 5.3 vs 9.3) and Remembering (median, 5 vs 11; mean, 5.7 vs 10.7). The overall adherence rate was 94%.ConclusionsOur results show a high rate of adherence to hemophilia prophylaxis by Polish adults. Problems with the management of clotting factor stocks and remembering about the injection of the clotting factor were identified as potential barriers to adherence in adults with hemophilia in Poland.

24 keywords...

hide…